MSI-H, short for microsatellite instability-high, describes a molecular feature found in roughly 4% of all solid tumors in which the cell’s DNA repair system has stopped working properly, allowing small repetitive DNA sequences called microsatellites to accumulate errors at an abnormally high rate. The designation matters enormously because MSI-H tumors tend to respond well to a class of drugs called immune checkpoint inhibitors, and MSI-H status was the first biomarker ever used by regulators to approve a cancer drug regardless of where in the body the tumor originated. Understanding what drives MSI-H, how it’s tested, and where it shows up changes the treatment conversation for a meaningful number of cancer patients.
How DNA Repair Breaks Down
Every time a cell copies its DNA before dividing, the machinery that duplicates the genetic code makes small mistakes. Normally, a set of proteins called the mismatch repair (MMR) system catches and fixes those errors. When MMR proteins stop functioning, the mistakes go uncorrected, and the overall mutation rate of the cell climbs sharply.1Frontiers in Molecular Biosciences. Mismatch Repair Pathway, Genome Stability and Cancer Microsatellites are especially vulnerable because their repetitive structure makes them prone to slippage during DNA copying. When MMR isn’t there to clean up the slippage, the microsatellites grow or shrink unpredictably from one cell division to the next. If enough of these microsatellite sites show instability when tested, the tumor is classified as MSI-H.
That flood of uncorrected mutations has a paradoxical consequence. Many of the new mutations fall within genes, producing abnormal proteins the body has never seen before. These abnormal proteins act like red flags for the immune system. Specifically, when microsatellite slippage happens inside a coding region of DNA, it can cause frameshift mutations that shift the entire reading frame of a gene, generating stretches of completely foreign protein that the immune system can potentially recognize and attack.2PubMed Central. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors This is the biological foundation for why MSI-H tumors are often responsive to immunotherapy.
Why Most MSI-H Tumors Are Sporadic
There are two main routes to a tumor becoming MSI-H. The first is Lynch syndrome, a hereditary condition in which a person inherits a defective copy of one of the MMR genes (most commonly MLH1, MSH2, MSH6, or PMS2). Lynch syndrome accounts for only a small fraction of MSI-H cancers. In colorectal cancer, for instance, Lynch syndrome causes about 3% of mismatch repair-deficient cases, while sporadic silencing of the MLH1 gene through a chemical modification called promoter hypermethylation accounts for roughly 12%.3Genetics in Medicine. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses In other words, the vast majority of MSI-H tumors arise from a non-inherited, tumor-specific event rather than an inherited gene mutation.
Distinguishing between these two causes matters for the patient and their family. Sporadic MSI-H tumors almost always show MLH1 methylation and frequently carry a mutation in the BRAF gene. When both are present, Lynch syndrome is essentially ruled out.4PubMed. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation The minority of cases in which MLH1 is lost but methylation and BRAF are absent are the ones that warrant genetic counseling for possible Lynch syndrome. Getting this triage right determines whether the patient’s blood relatives need to start enhanced cancer surveillance.
MSI-L Is Not the Same Thing
You’ll sometimes see tumors classified as MSI-L (microsatellite instability-low) or MSS (microsatellite stable). These labels are not just milder versions of MSI-H. MSI-L tumors behave much more like MSS tumors in terms of their biology, their clinical features, and their response to therapy. Unlike MSI-H tumors, MSI-L tumors appear to develop through a different genetic pathway altogether, one driven by large-scale chromosomal rearrangements rather than accumulating small point mutations.5PubMed Central. Colorectal carcinogenesis: MSI-H versus MSI-L For practical purposes, when oncologists talk about the benefits of MSI status, they mean MSI-H specifically. An MSI-L result does not open the door to the same treatment options.
How MSI-H Is Detected
There are three main ways to test for MSI-H, and they approach the question from slightly different angles. Immunohistochemistry (IHC) stains a tissue sample to see whether the four major MMR proteins are present. If one or more are missing, the tumor is called mismatch repair-deficient (dMMR), which is functionally equivalent to MSI-H in most situations. PCR-based testing directly measures instability at a panel of microsatellite markers. Next-generation sequencing (NGS) can assess hundreds or thousands of microsatellite loci at once during broader genomic profiling.
In a comparison of all three methods in colorectal cancer, the agreement was very high. PCR and NGS showed near-perfect concordance, with IHC close behind.6PubMed Central. Comparison of immunohistochemistry, PCR, and NGS for the evaluation of mismatch repair deficiency and microsatellite instability in colorectal cancer: a retrospective study A large study of over 190,000 tumor samples that had both NGS and IHC testing found a final discordance rate of just 0.31% after pathologist review.7PubMed Central. Analysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair From Solid Tumors So while the methods are not perfectly interchangeable, disagreements are rare enough that any of the three is considered acceptable for guiding treatment decisions.
That said, NGS may catch some cases that PCR misses, particularly in cancers outside the colorectum where the standard PCR panels were not originally designed. A study of over 35,000 Chinese cancer patients found instances where NGS flagged tumors as MSI-H that PCR had called stable, and follow-up testing with methylation and mutation data supported the NGS classification.8npj Precision Oncology. Applying next-generation sequencing to detect microsatellite instability in pan-cancer patients: a retrospective study of 35,563 Chinese cases This is one reason many comprehensive genomic profiling panels now include MSI assessment as a standard feature.
The Tissue-Agnostic Treatment Revolution
In 2017, the FDA approved pembrolizumab (Keytruda) for any solid tumor that tested MSI-H or dMMR and had progressed after prior treatment. This was genuinely unprecedented. Cancer drugs had always been approved for a specific organ: a breast cancer drug, a lung cancer drug, a colon cancer drug. Approving a drug based purely on a molecular feature, regardless of where the tumor started, marked a fundamental change in how oncology thinks about treatment.9PubMed Central. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine MSI-H was one of the first biomarkers to earn this tissue-agnostic designation, and it has since been joined by a handful of others including tumor mutational burden-high and NTRK fusions.10PubMed Central. Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates
The rationale is straightforward. Because MSI-H tumors produce so many mutant proteins, the immune system already has material to work with. Checkpoint inhibitors like pembrolizumab remove a brake that tumors use to hide from immune cells, and in MSI-H cancers, once that brake is removed, the immune system has an unusually rich set of targets to attack.
How Well Immunotherapy Works in MSI-H Cancers
The clinical results have been striking, especially in colorectal cancer. In the KEYNOTE-177 trial, pembrolizumab was compared head-to-head against standard chemotherapy as initial treatment for people with MSI-H metastatic colorectal cancer. About 44% of patients on pembrolizumab had their tumors shrink meaningfully, compared with 33% on chemotherapy. Perhaps more telling, among those who responded, 83% in the pembrolizumab group still had ongoing responses at two years, versus 35% in the chemotherapy group.11PubMed. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer The durability of response is one of the most notable features: when MSI-H cancers respond to immunotherapy, the benefit often lasts far longer than what chemotherapy typically offers.
Beyond colorectal cancer, the KEYNOTE-158 trial tested pembrolizumab across a wide range of MSI-H solid tumors. Updated results with several years of follow-up showed an overall response rate of about 34%, with a median duration of response over five years for those who did respond.12PubMed. Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial Endometrial cancer stood out as particularly responsive, with a 48% response rate in MSI-H patients and a median duration of response that had not yet been reached after years of follow-up.13PubMed Central. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study Endometrial cancer is one of the cancers where MSI-H is most commonly found, and checkpoint inhibitors have become a significant part of the treatment landscape for it.14PubMed Central. Immunotherapy in endometrial cancer
Combination immunotherapy has pushed results further. A trial of nivolumab plus ipilimumab versus chemotherapy in MSI-H metastatic colorectal cancer showed that 72% of patients on the combination were still free of disease progression at two years, compared with 14% on chemotherapy.15PubMed. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer Across multiple studies, the nivolumab-ipilimumab combination has produced response rates ranging from about 31% to 69%, depending on the setting and patient population.16PubMed. Safety and Efficacy of Nivolumab Plus Ipilimumab in Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Cancer: A Systematic Review
When MSI-H Does Not Guarantee a Response
Despite the overall encouraging numbers, a substantial minority of MSI-H patients do not respond to immunotherapy. The pan-cancer response rate of around 34% means roughly two out of three patients with MSI-H tumors outside the colorectum don’t see a meaningful response. Understanding why some MSI-H tumors resist immunotherapy is an active area of research.
One factor is the underlying cause of the MMR deficiency. Not all MSI-H tumors have the same immune environment. In endometrial cancer, tumors that became MSI-H through MLH1 hypermethylation had worse overall survival and showed weaker immune activation markers compared to tumors with actual MLH1 gene mutations, including lower PD-L1 expression and less immune cell infiltration.17Gynecologic Oncology. Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 “Lynch-like” mismatch repair gene mutation In other words, two tumors that both test MSI-H can have quite different levels of immune engagement.
Mutations in genes involved in antigen presentation, such as B2M, have been proposed as potential escape routes that tumors might use to evade immune attack. However, the picture is more complex than initially feared. A study of MSI-H colorectal cancers found that patients with B2M mutations did not show higher rates of resistance to checkpoint inhibitors, and those with JAK1/2 mutations actually had better responses than those without.18PubMed Central. B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy The takeaway is that these mutations should not automatically exclude patients from receiving immunotherapy.
The gut microbiome is emerging as another piece of the puzzle. Research on MSI-H gastrointestinal cancer patients found that the bacterial communities in the gut differed between those who responded to immunotherapy and those who didn’t. When stool from responders was transplanted into mice, it enhanced the immune response against tumors compared to stool from non-responders.19Cell Reports Medicine. Gut microbiome and metabolome signatures in MSI-H/dMMR gastrointestinal cancer patients during immunotherapy This line of investigation is still early, but it suggests that the conversation between gut bacteria and the immune system may help explain why two patients with the same MSI-H label have very different treatment outcomes.20Frontiers in Cellular and Infection Microbiology. Gut microbiome-mediated primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR colorectal cancer: mechanisms, biomarkers, and therapeutic implications-a narrative review
Which Cancers Are Most Likely to Be MSI-H
MSI-H is not evenly distributed across cancer types. A large genomic study across 39 cancer types found MSI in about 3.8% of all cancers assessed, present in 27 different tumor types.21PubMed Central. Landscape of Microsatellite Instability Across 39 Cancer Types Endometrial and colorectal cancers have the highest rates, with MSI-H showing up in roughly a quarter to a third of endometrial cancers and around 15% of colorectal cancers, depending on the study population. Gastric and small bowel cancers also have meaningful MSI-H rates. But the study also identified MSI-H in cancer types where it had not been well described before, including adrenocortical carcinoma, cervical cancer, and mesothelioma. This is why many oncologists now recommend MSI testing for all advanced solid tumors, not just the cancer types historically associated with it.
The Lynch Syndrome Screening Question
Because MSI-H testing is now routine for many cancers, it doubles as a screening gateway for Lynch syndrome. When a tumor tests MSI-H and additional workup rules out sporadic hypermethylation, the patient may be referred for germline genetic testing. If a Lynch syndrome mutation is confirmed, it has implications well beyond the current cancer. Lynch syndrome carriers face elevated lifetime risks for colorectal, endometrial, ovarian, urinary tract, and several other cancers. Their first-degree relatives have a 50% chance of carrying the same mutation.
Screening algorithms typically use concurrent IHC for MMR proteins and BRAF mutation testing to efficiently sort patients. A positive BRAF result in the context of MLH1 loss points strongly toward sporadic disease, while its absence triggers referral for genetic counseling.22PubMed Central. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch Syndrome However, tumor-based screening is not a failsafe. Some Lynch syndrome patients can be missed by MSI testing alone, and combining thorough family history with universal tumor testing provides a more complete screening approach.23Cancer Research and Treatment. Universal Screening for Lynch Syndrome Compared with Pedigree-Based Screening: 10-Year Experience in a Tertiary Hospital
The psychological side of this deserves mention. Receiving a Lynch syndrome diagnosis carries emotional weight beyond the immediate cancer treatment. Studies have found that newly identified carriers experience a temporary increase in anxiety and depression scores after disclosure, though these tend to normalize within six to twelve months. The diagnosis also influences family planning decisions, and there is growing interest in options like preimplantation genetic testing among carriers.24PubMed. Psychosocial Impact of Lynch Syndrome on Affected Individuals and Families
MSI-H Versus POLE Mutations
MSI-H tumors are not the only hypermutated cancers. Tumors with mutations in the POLE gene, which encodes a DNA copying enzyme, can also accumulate very high numbers of mutations and may respond to immunotherapy for similar reasons. But the two are genetically distinct. MSI-H tumors tend to have a particularly high burden of small insertions and deletions (the kind caused by microsatellite slippage), while POLE-mutated tumors accumulate more single-letter substitutions. In one comparison, the median mutation burden in MSI-H tumors was about 84 mutations per megabase of DNA, compared to about 13 per megabase in POLE-mutated tumors, though some POLE-mutated tumors can reach extremely high mutation burdens exceeding 200 per megabase depending on the specific POLE variant involved.25PubMed Central. Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors26PubMed Central. Clinicopathologic Analysis of Five Patients with POLE-Mutated Colorectal Cancer in a Single Korean Institute
In endometrial cancer, where molecular classification now guides treatment, a tumor can occasionally carry both a POLE mutation and MMR deficiency. These overlap cases tend to have the highest mutation burdens of all and pose a classification challenge, but they generally carry a favorable prognosis.27Gynecologic Oncology. Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification
Constitutional Mismatch Repair Deficiency in Children
A rare and severe variant of inherited MMR deficiency deserves its own mention. Constitutional mismatch repair deficiency (CMMRD) occurs when a child inherits defective copies of an MMR gene from both parents, rather than just one as in Lynch syndrome. The result is a dramatically accelerated cancer risk beginning in childhood. In an international cohort, tumors developed in 15 different organs, with brain tumors being the most common (about half of all cancers), followed by gastrointestinal and blood cancers.28The Lancet Oncology. Constitutional mismatch repair deficiency as a paradigm for precision medicine: an international cohort study The median age of tumor onset varies by the specific gene involved, ranging from as young as 3 years for MSH2-related cases to around 15 years for PMS2-related cases.29PubMed Central. Constitutional Mismatch Repair Deficiency: Scoping Review of a Cancer‐Predisposition Syndrome With Distinctive Cutaneous Findings
One clinical clue to CMMRD is the presence of café-au-lait spots on the skin, which were found in all affected children in one series. Many families with CMMRD have a history of parental consanguinity. An important diagnostic nuance: while IHC was highly reliable for identifying MMR deficiency in these patients’ tumors, standard microsatellite instability testing by PCR was neither sensitive nor specific for making the diagnosis, likely because the constitutional nature of the defect creates a different background instability pattern than what standard tests are calibrated to detect.30European Journal of Cancer. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium The high mutation burden in these tumors does, however, make them potential candidates for immunotherapy, and checkpoint inhibitors are increasingly part of the treatment approach.
Liquid Biopsy and Harder-to-Test Cancers
Not every cancer is easy to biopsy. Prostate cancer, for instance, is often diagnosed without a large tissue sample suitable for MSI testing, and pancreatic cancer can be difficult to access. Liquid biopsy, which analyzes tumor DNA circulating in the blood, is being explored as a way to identify MSI-H status without needing a tissue sample. In prostate cancer, researchers demonstrated that MSI-H detected by circulating tumor DNA was feasible in clinical practice and that patients identified this way showed strong responses to pembrolizumab.31PubMed Central. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA Similarly, in pancreatic cancer, liquid biopsy identified MSI-H patients who went on to have a 77% response rate to immunotherapy, with most responders still in response after a median follow-up of nearly two years.32PubMed Central. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer For cancers where tissue is scarce or hard to obtain, blood-based MSI testing could meaningfully expand the pool of patients who get matched to effective therapy.
Universal testing strategies also carry equity implications. When Lynch syndrome screening depends on a clinician thinking to order it or a patient having the resources to pursue genetic counseling, disparities in access follow. Systematic, universal approaches to MSI testing in all colorectal cancer patients can help reduce referral bias that has historically led to underdiagnosis of Lynch syndrome in minority populations.33PubMed Central. Cost-effectiveness of Lynch syndrome screening in colorectal cancer: universal germline vs sequential screening As testing technology gets cheaper and more integrated into standard genomic panels, the barriers to routine MSI assessment continue to fall.